Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin and trazodone combination for treatment-resistant depression
2024-512911-34-00Phase 2Authorised
- Sponsor
- GHU Paris psychiatrie & neurosciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin and trazodone in treatment-resistant depression (TRD) (5 arms), sponsored by GHU Paris psychiatrie & neurosciences. Primary endpoint: MADRS mean change at 1 month. Planned start Jun 2025; status: authorised.
02
Drugs
psilocybintrazodone
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2024-512911-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512911-34-00.